- 1/5 Read more: Changes to conventional cohort eligibility criteria
- 2/5 Recruitment to Taltz has restarted
- 3/5 Our BADBIR Annual Update for 2024 is now available on the website here for everyone to read
- 4/5 Patients diagnosed with Generalised Pustular Psoriasis are eligible on Spevigo (spesolimab) or conventional treatment
- 5/5 Reminder that we currently recruit for patients on Sotyktu (deucravacitinib)
Top
BADBIR is based at the University of Manchester.